| Literature DB >> 36010008 |
Costanza Vicentini1, Lorenzo Vola1, Christian Previti1, Valerio Brescia2, Francesca Dal Mas3, Carla Maria Zotti1, Fabrizio Bert1.
Abstract
Upper-respiratory-tract infections (URTIs) are among the main causes of antibiotic prescriptions in pediatric patients. Over one-third of all antibiotic prescriptions for URTIs in children are estimated to be inappropriate, as the majority of URTIs are caused by viral agents. Several strategies, including clinical scoring algorithms and different point-of-care tests (POCTs) have been developed to help discriminate bacterial from viral URTIs in the outpatient clinical setting. A systematic review of the literature was conducted following PRISMA guidelines with the objective of summarizing evidence from health-economic evaluations on the use of POCT for URTIs in pediatric outpatients. A total of 3375 records identified from four databases and other sources were screened, of which 8 met the inclusion criteria. Four studies were classified as being of high reporting quality, and three were of medium quality. Five out of eight studies concluded in favor of strategies that included POCTs, with an additional study finding several POCTs to be cost-effective compared to usual care but over an acceptable WTP threshold. This review found POCT could be a valuable tool for antimicrobial stewardship strategies targeted towards childhood URTIs in primary care.Entities:
Keywords: C-reactive protein tests; children; health–economic evaluations; nucleic acid amplification tests; point-of-care tests; primary care; rapid antigen-detection tests; upper-respiratory-tract infections
Year: 2022 PMID: 36010008 PMCID: PMC9404955 DOI: 10.3390/antibiotics11081139
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1PRISMA 2020 flow diagram.
Characteristics of studies reporting economic evaluations of antimicrobial stewardship strategies including point-of-care testing in pediatric patients with respiratory-tract infections.
| First Author, Year of Publication | Country | Population | Setting | Condition | POCT | Implementation Strategy for POCT | Non-POCT Comparator | Study Quality (CHEERS Score) |
|---|---|---|---|---|---|---|---|---|
| Van Howe, 2006 [ | USA | Children (age not specified) | Primary care | URTI | RADT | (1) Standalone RADT, (2) RADT with culture confirmation of negative | (1) No treatment, (2) treat all suspected cases, (3) perform culture | 21 |
| Giraldez-Garcia, 2011 [ | Spain | Children (aged 2–14 years) | Primary care | URTI | RADT | (1) Standalone RADT, (2) RADT with culture confirmation of negative | (1) Treat all suspected cases, (2) perform culture, (3) clinical scoring tool | 22 |
| Malecki, 2017 [ | Poland | Children (aged 2–15 years) | Primary healthcare centers | URTI | RADT | Standalone RADT | Routine clinical practice | 11 |
| Lubell, 2018 [ | Vietnam | Both children and adults (aged 1–65 years) | Primary healthcare centers | RTI | CRP | Standalone POC CRP | Routine clinical practice | 21 |
| Behnamfar, 2019 [ | Iran | Children (aged 4–12.5 years) | Outpatient (GPs, pediatricians) | URTI | RADT | (1) Standalone RADT, (2) RADT plus culture, (3) RADT with culture confirmation of negative results | (1) Treat all suspected cases, (2) no treatment, (3) perform culture | 21 |
| Fraser, 2020 [ | UK | Both children (aged 5–14 years) and adults (aged 15–75, modeled separately) | Primary and secondary care (modeled separately) | URTI | 17 different RADTs and four molecular tests | POCT + clinical | Clinical assessment incorporating clinical scoring tools | 27 |
| Schneider, 2020 [ | UK | Both children and adults (age not specified) | Outpatient | URTI and otitis media | CRP, dual-biomarker (CRP and MxA), hypothetical test | Standalone POCT | Routine clinical practice | 22 |
| Bilir, 2021 [ | USA | Both children (<18 years) and adults (≥18 years) | Ambulatory care | URTI | NAAT vs. RADT | (1) Standalone POCT NAAT, (2) RADT with culture confirmation of negative results | (Only in budget impact analysis) All diagnostic techniques | 24 |
CRP: C-reactive protein; MxA: myxovirus-resistance protein A; NAAT: POC nucleic acid amplification test; POCT: point-of-care test; RADT: rapid antigen-detection test; URTI: upper-respiratory-tract infection.
Methodological characteristics and results of economic evaluations of antimicrobial stewardship strategies including point-of-care testing in pediatric patients with respiratory-tract infections.
| First Author, Year of Publication | Study Characteristics | Results | ||||||
|---|---|---|---|---|---|---|---|---|
| Study Design | Model-Based vs. Trial-Based | Time Horizon | Perspective | Outcomes | Sensitivity Analysis | Base-Case Results | Sensitivity-Analysis Results | |
| Van Howe, 2006 [ | CUA | Model-based (decision tree) | NR | Societal, payer | Cost–effectiveness | DSA | RADT had the best cost–utility result from the payer perspective. | Considerable overlap among all of the options except (1) treating all patients and (2) observing all patients. |
| Giraldez-Garcia, 2011 [ | CEA | Model-based (decision tree) | NR | Healthcare system | Cost–effectiveness, ICER, total annual cost | DSA | RADT combined with clinical score was the most cost-effective strategy. | Standalone RADT was the most cost-effective strategy when the sensitivity and specificity of clinical score decreased. |
| Malecki, 2017 [ | CIA | Trial-based | NR | Healthcare system | Cost per patient | Not performed | Threshold cost per test set at PLN 12 | Not performed |
| Lubell, 2018 [ | CBA | Trial-based | 14 days | Societal | Cost per patient | DSA | CRP testing was not cost-beneficial compared to usual care. | If adherence to test result increased, POCT would be cost-beneficial. |
| Behnamfar, 2019 [ | CUA | Model-based (decision tree) | NR | Societal, payer | Cost–effectiveness, ICER | DSA | RADT was the most cost-effective strategy. | (1) RADT + culture and (2) culture were the most cost-effective strategies in some scenarios (varying the probability of peritonsillar abscess). |
| Fraser, 2020 [ | CUA | Model-based (decision tree) | 1 year | Healthcare system and Personal Social Services perspective | Cost–effectiveness, ICER | PSA | Children’s primary care model: usual care was dominant compared to 4 tests; the other 17 tests were cost-effective compared to usual care but over WTP. | In line with deterministic results. |
| Schneider, 2020 [ | BIA | Model-based | 1 year | Healthcare system | Cost per patient, total annual cost | DSA | All POCTs were cost-saving compared to status quo: hypothetical test −54%, CRP + MxA −27%, and CRP −11%. | Confirmed usual care to |
| Bilir, 2021 [ | CUA, BIA | Model-based (decision tree) | CUA: 1 year, BIA: 5 years | Payer, third-party payer | Cost per patient, cost–effectiveness, ICER, total costs over 5 years | DSA and PSA | POC NAAT was dominant compared to RADT + culture. | POC NAAT remained cost-saving across all simulations. |
BIA: budget–impact analysis; CBA: cost–benefit analysis; CEA: cost–effectiveness analysis; CIA: cost–identification analysis; CUA: cost–utility analysis; DSA: deterministic-sensitivity analysis; ICER: incremental-cost–effectiveness ratio; NR: not reported; PSA: probabilistic-sensitivity analysis; WTP: willingness to pay.
Figure 2Flow chart summarizing the 2012 Infectious Diseases Society of America (IDSA) guidelines for managing group A streptococcal pharyngitis (GAS) [28]. RADT: rapid antigen-detection test; URTI: upper-respiratory-tract infection.
Figure 3Flow chart summarizing the American Academy of Family Physicians (Leawood, KS, USA) guidelines for managing group A streptococcal pharyngitis (GAS) using a clinical scoring tool in combination with a rapid antigen-detection test (RADT) [29]. URTI: upper-respiratory-tract infection.